Evidence map›Paper›PMID 23755196›Full record

ArticlePloS one2013

An ethanolic extract of Lindera obtusiloba stems, YJP-14, improves endothelial dysfunction, metabolic parameters and physical performance in diabetic db/db mice.

Jung-Ok Lee, Cyril Auger, Dong Hyun Park, Moonkyu Kang, Min-Ho Oak, Kyoung Rak Kim, Valérie B Schini-Kerth

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01836172 (Multicenter, Randomized, Double Blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Safety and Efficacy of YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01836172 phase2unknown statusnot on this map

Multicenter, Randomized, Double Blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Safety and Efficacy of YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus

TypeinterventionalSponsorHan Wha Pharma Co., Ltd.Ran2013 to 2017Enrolled136ConditionsDiabetic ComplicationArmsYJP-14
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Nutrients · 2024
    Article
  2. A StandardizedPlants (Basel, Switzerland) · 2021
    Article
  3. Mitigating Effect ofMolecules (Basel, Switzerland) · 2021
    Article
  4. Article
  5. Therapeutic Potential ofPlants (Basel, Switzerland) · 2020
    Review
  6. Article
  7. Effects of metformin on endothelial function in type 2 diabetes.Experimental and therapeutic medicine · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Jung-Ok LeeUMR CNRS 7213, Laboratoire de Biophotonique et Pharmacologie, Faculté de Pharmacie, Université de Strasbourg, Illkirch, France.
Cyril Auger
Dong Hyun Park
Moonkyu Kang
Min-Ho Oak
Kyoung Rak Kim
Valérie B Schini-Kerth
Dongwha Pharm (South Korea) · KRUniversité de Strasbourg · FRLaboratoire de Biophotonique et Pharmacologie · FRMokpo National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lindera obtusiloba is a medicinal herb traditionally used in Asia for improvement of blood circulation, treatment of inflammation, and prevention of liver damage. A previous study has shown that an ethanolic extract of Lindera obtusiloba stems (LOE) has vasoprotective and antihypertensive effects. The possibility that Lindera obtusiloba improves endothelial function and metabolic parameters in type 2 diabetes mellitus (T2DM) remains to be examined. Therefore, the aim of the present study was to determine the potential of LOE to prevent the development of an endothelial dysfunction, and improve metabolic parameters including hyperglycemia, albuminuria and physical exercise capacity in db/db mice, an experimental model of T2DM. The effect of LOE (100 mg/kg/day by gavage for 8 weeks) on these parameters was compared to that of an oral antidiabetic drug, pioglitazone (30 mg/kg/day by gavage). Reduced blood glucose level, body weight and albumin-creatinine ratio were observed in the group receiving LOE compared to the control db/db group. The LOE treatment improved endothelium-dependent relaxations, abolished endothelium-dependent contractions to acetylcholine in the aorta, and normalized the increased vascular oxidative stress and expression of NADPH oxidase, cyclooxygenases, angiotensin II, angiotensin type 1 receptors and peroxynitrite and the decreased expression of endothelial NO synthase in db/db mice. The angiotensin-converting enzyme (ACE) activity was reduced in the LOE group compared to that in the control db/db group. LOE also inhibited the activity of purified ACE, COX-1 and COX-2 in a dose-dependent manner. In addition, LOE improved physical exercise capacity. Thus, the present findings indicate that LOE has a beneficial effect on the vascular system in db/db mice by improving endothelium-dependent relaxations and vascular oxidative stress most likely by normalizing the angiotensin system, and also on metabolic parameters, and these effects are associated with an enhanced physical exercise capacity.

Indexed as

AlbuminuriaAngiotensin IIAnimalsAortaBlood GlucoseBody WeightDiabetes Mellitus, Type 2Disease Models, AnimalEndothelium, VascularEthanolExercise ToleranceGene ExpressionHumansHyperglycemiaHypoglycemic AgentsLinderaAngiotensin IIBlood GlucoseEthanolHypoglycemic AgentsNADPH OxidasesNitric Oxide Synthase Type IIINos3 protein, mousePioglitazonePlant ExtractsProstaglandin-Endoperoxide SynthasesReceptor, Angiotensin, Type 1Thiazolidinediones

Identifiers

PMID23755196
PMCPMC3670856
OpenAlexW2048273113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.